Literature DB >> 18560613

The role of the endogenous cannabinoid system in drug addiction.

D Parolaro1, T Rubino.   

Abstract

This review aims to present the more recent knowledge on the role of the endocannabinoid system in drug addiction. For a long time, dopamine has been consistently associated with the reinforcing effects of most drugs of abuse but, recently, pharmacological evidence points to the possibility that pharmacological management of the endocannabinoid system might not only block the direct reinforcing effect of cannabis, opioids, nicotine and ethanol, but also prevent the relapse to various drugs of abuse including opioids, cocaine, nicotine, alcohol and amphetamine. Preclinical and clinical studies suggest that the manipulation of the endocannabinoid system through the CB(1) receptor antagonist SR-141716A (rimonabant) might constitute a new therapeutical strategy for treating addiction across different classes of abused drugs. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560613

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  13 in total

1.  Temporally dependent changes in cocaine-induced synaptic plasticity in the nucleus accumbens shell are reversed by D1-like dopamine receptor stimulation.

Authors:  Pavel I Ortinski; Fair M Vassoler; Gregory C Carlson; R Christopher Pierce
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

Review 2.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

Review 3.  Therapeutic potential of monoacylglycerol lipase inhibitors.

Authors:  Melinda M Mulvihill; Daniel K Nomura
Journal:  Life Sci       Date:  2012-11-08       Impact factor: 5.037

Review 4.  Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls.

Authors:  Matthew W Buczynski; Loren H Parsons
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration.

Authors:  Jesse S Rodriguez; Sherin Y Boctor; Luke C Flores; Clyde F Phelix; Joe L Martinez
Journal:  Neurosci Lett       Date:  2010-12-15       Impact factor: 3.046

6.  The endocannabinoid system tonically regulates inhibitory transmission and depresses the effect of ethanol in central amygdala.

Authors:  Marisa Roberto; Maureen Cruz; Michal Bajo; George R Siggins; Loren H Parsons; Paul Schweitzer
Journal:  Neuropsychopharmacology       Date:  2010-05-12       Impact factor: 7.853

7.  Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB₂ receptors.

Authors:  Auxiliadora Aracil-Fernández; José M Trigo; María S García-Gutiérrez; Antonio Ortega-Álvaro; Alexander Ternianov; Daniela Navarro; Patricia Robledo; Pere Berbel; Rafael Maldonado; Jorge Manzanares
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

8.  Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice.

Authors:  Carmen Manzanedo; Marta Rodríguez-Arias; Manuel Daza-Losada; Concepción Maldonado; María A Aguilar; José Miñarro
Journal:  Behav Brain Funct       Date:  2010-03-22       Impact factor: 3.759

9.  Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice.

Authors:  Xia Li; Alexander F Hoffman; Xiao-Qing Peng; Carl R Lupica; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

10.  Repeated cocaine administration upregulates CB2 receptor expression in striatal medium-spiny neurons that express dopamine D1 receptors in mice.

Authors:  Hai-Ying Zhang; Lindsay De Biase; Ramesh Chandra; Hui Shen; Qing-Rong Liu; Eliot Gardner; Mary Kay Lobo; Zheng-Xiong Xi
Journal:  Acta Pharmacol Sin       Date:  2021-07-27       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.